The response to agonist stimulation was also greatly limited in pDCs from severe COVID-19 patients compared to healthy donors and patients with mild symptoms/asymptomatic, notably as shown by the level of activation markers (CD83, CD80, and PD-L1; Fig. 2f, g; red arrows). This evidence concerns the gene CD80 and COVID-19.